摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

((S)-5-amino-1-{[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-methyl}-pentyl)-carbamic acid tert-butyl ester | 1196038-62-6

中文名称
——
中文别名
——
英文名称
((S)-5-amino-1-{[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-methyl}-pentyl)-carbamic acid tert-butyl ester
英文别名
tert-butyl N-[(2S)-6-amino-1-[(3,5-diamino-6-chloropyrazine-2-carbonyl)amino]hexan-2-yl]carbamate
((S)-5-amino-1-{[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-methyl}-pentyl)-carbamic acid tert-butyl ester化学式
CAS
1196038-62-6
化学式
C16H28ClN7O3
mdl
——
分子量
401.896
InChiKey
NLNJMDUCXXDCHQ-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    27
  • 可旋转键数:
    10
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    171
  • 氢给体数:
    5
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3,5-DIAMINO-6-CHLORO-PYRAZINE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS EPITHELIAL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF AIRWAY DISEASES
    申请人:Collingwood Stephen Paul
    公开号:US20110059989A1
    公开(公告)日:2011-03-10
    A compound of Formula I in free or salt or solvate form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    公式I的化合物以自由或盐或溶剂的形式存在,其中R1、R2、R3、R4、R5、R6、R7、R8和R9的含义如规范中所示,可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了包含该化合物的制药组合物和制备该化合物的过程。
  • Organic Comopunds
    申请人:Collingwood Stephen Paul
    公开号:US20110201625A1
    公开(公告)日:2011-08-18
    A compound of Formula I or a hydrate or solvate thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    化合物I的配方或其水合物或溶剂化物,其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10的含义如规范中所示,可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了含有该化合物的制药组合物和制备该化合物的过程。
  • Pyrazine derivatives as ENAC blockers
    申请人:Novartis AG
    公开号:US08236808B2
    公开(公告)日:2012-08-07
    A compound of Formula I or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    公式I的化合物或其水合物或溶剂化物,其中R1,R2,R3,R4,R5,R6,R7,R8,R9和R10具有规范中指示的含义,可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了包含这些化合物的制药组合物和制备这些化合物的过程。
  • 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
    申请人:Collingwood Stephen Paul
    公开号:US08664228B2
    公开(公告)日:2014-03-04
    A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    具有公式I的化合物,以自由或盐或溶剂形式存在,其中R1,R2,R3,R4,R5,R6,R7,R8和R9的含义如规范中所示,可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了包含这些化合物的制药组合物和制备这些化合物的过程。
  • PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS
    申请人:Novartis AG
    公开号:EP2300010B1
    公开(公告)日:2015-03-04
查看更多